Health state | Estimate* | Range | Distribution† | Source |
---|---|---|---|---|
All pathways | ||||
Baseline | 0.4 | 0.35–0.45 | β (2,2) | Symptomatic off treatment |
Asymptomatic off treatment | 1 | – | – | Ranking exercise |
Symptomatic off treatment | 0.4 | 0.35–0.45 | β (2,2) | Ranking exercise |
Conservative surgery | – | – | – | post-surgery |
Symptomatic post-conservative surgery | 0.35 | 0.25–0.45 | β (2,2) | Ranking exercise |
Asymptomatic post-conservative surgery | 0.8 | 0.75–0.85 | β (2,2) | Ranking exercise |
Hysterectomy | – | – | – | post-surgery |
Symptomatic post-hysterectomy | 0.25 | 0.15–0.35 | β (2,2) | Ranking exercise |
Asymptomatic post-hysterectomy | 0.7 | 0.65–0.75 | β (2,2) | Ranking exercise |
DMPA/COCP | ||||
Asymptomatic initial treatment | 0.7 | 0.65–0.75 | β (2,2) | Ranking exercise |
Symptomatic initial treatment | 0.35 | 0.25–0.45 | β (2,2) | Ranking exercise |
Change treatment (second treatment) | – | – | – | Symptomatic second treatment |
Asymptomatic second treatment | 0.7 | 0.65–0.75 | β (2,2) | Ranking exercise |
Symptomatic second treatment | 0.25 | 0.15–0.35 | β (2,2) | Ranking exercise |
LNG-IUS/no treatment | ||||
Asymptomatic on LNG-IUS | 0.8 | 0.75–0.85 | β (2,2) | Ranking exercise |
Symptomatic on LNG-IUS | 0.35 | 0.25–0.45 | β (2,2) | Ranking exercise |
Change treatment | – | – | – | Symptomatic second treatment |
Asymptomatic second treatment | 0.7 | 0.65–0.75 | β (2,2) | Ranking exercise |
Symptomatic second treatment | 0.3 | 0.25–0.35 | β (2,2) | Ranking exercise |
*The estimate reflects the values provided by clinicians and is used only to set the range of values for the analysis.
†These β distributions are applied within the ranges shown in the previous column, not across the full range of possible values from 0 to 1. Thus, the sampled value for any asymptomatic state will always be higher than the sampled value for the corresponding symptomatic state.
COCP, combined oral contraceptive pill; DMPA, depot-medroxyprogesterone acetate; LNG-IUS, levonorgestrel-releasing intrauterine device.